Do analysts prefer BOLD or CAMP?

CAMP4 Therapeutics has a consensus target price of $9.56, suggesting a potential upside of 120.95%. Given CAMP4 Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CAMP4 Therapeutics is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CAMP4 Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

Do analysts rate MGNX or BOLD?

MacroGenics presently has a consensus price target of $6.33, suggesting a potential upside of 51.33%. Given MacroGenics' stronger consensus rating and higher possible upside, research analysts clearly believe MacroGenics is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MGNX or BOLD more profitable?

Boundless Bio has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Boundless Bio's return on equity of -70.89% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets MacroGenics -8.70% -109.26% -18.70% Boundless Bio N/A -70.89% -47.37%

Do analysts recommend BOLD or AKBA?

Akebia Therapeutics has a consensus target price of $3.75, suggesting a potential upside of 284.22%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Akebia Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts rate PRQR or BOLD?

ProQR Therapeutics currently has a consensus target price of $7.50, suggesting a potential upside of 259.71%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe ProQR Therapeutics is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProQR Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend BOLD or RNA?

Avidity Biosciences has a consensus price target of $63.85, indicating a potential upside of 342.45%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avidity Biosciences 1 Sell rating(s) 11 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.29

Is BOLD or RNA more profitable?

Avidity Biosciences' return on equity of 0.00% beat Boundless Bio's return on equity. Company Net Margins Return on Equity Return on Assets Boundless Bio N/A -70.89% -47.37% Avidity Biosciences N/A N/A N/A

Boundless Bio (BOLD) Competitors

$2.86 -0.03 (-0.90%)

As of 02:23 PM Eastern

Compare

BOLD vs. CAMP, MGNX, AKBA, PRQR, and RNA

Should you buy Boundless Bio stock or one of its competitors? Boundless Bio's main competitors and comparable companies include CAMP4 Therapeutics (CAMP), MacroGenics (MGNX), Akebia Therapeutics (AKBA), ProQR Therapeutics (PRQR), and Avidity Biosciences (RNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Boundless Bio compare to CAMP4 Therapeutics?

Boundless Bio (NASDAQ:BOLD) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Boundless Bio has higher earnings, but lower revenue than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A
CAMP4 Therapeutics	$3.50M	77.59	-$80.40M	-$2.32	N/A

In the previous week, CAMP4 Therapeutics had 8 more articles in the media than Boundless Bio. MarketBeat recorded 9 mentions for CAMP4 Therapeutics and 1 mentions for Boundless Bio. CAMP4 Therapeutics' average media sentiment score of 0.72 beat Boundless Bio's score of -0.33 indicating that CAMP4 Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Boundless Bio	Neutral
CAMP4 Therapeutics	Positive

Boundless Bio has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market. Comparatively, CAMP4 Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Boundless Bio has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Boundless Bio's return on equity of -70.89% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-70.89%	-47.37%
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%

CAMP4 Therapeutics has a consensus target price of $9.56, suggesting a potential upside of 120.95%. Given CAMP4 Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CAMP4 Therapeutics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

CAMP4 Therapeutics beats Boundless Bio on 8 of the 13 factors compared between the two stocks.

How does Boundless Bio compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and Boundless Bio (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

MacroGenics presently has a consensus price target of $6.33, suggesting a potential upside of 51.33%. Given MacroGenics' stronger consensus rating and higher possible upside, research analysts clearly believe MacroGenics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

96.9% of MacroGenics shares are held by institutional investors. 13.6% of MacroGenics shares are held by insiders. Comparatively, 23.1% of Boundless Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Boundless Bio has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Boundless Bio's return on equity of -70.89% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
Boundless Bio	N/A	-70.89%	-47.37%

MacroGenics has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Boundless Bio has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market.

Boundless Bio has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$175.14M	1.52	-$74.62M	-$0.22	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A

In the previous week, MacroGenics had 2 more articles in the media than Boundless Bio. MarketBeat recorded 3 mentions for MacroGenics and 1 mentions for Boundless Bio. MacroGenics' average media sentiment score of 1.52 beat Boundless Bio's score of -0.33 indicating that MacroGenics is being referred to more favorably in the media.

Company	Overall Sentiment
MacroGenics	Very Positive
Boundless Bio	Neutral

Summary

MacroGenics beats Boundless Bio on 10 of the 15 factors compared between the two stocks.

How does Boundless Bio compare to Akebia Therapeutics?

Boundless Bio (NASDAQ:BOLD) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Akebia Therapeutics has a consensus target price of $3.75, suggesting a potential upside of 284.22%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Boundless Bio has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Boundless Bio's return on equity of -70.89% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-70.89%	-47.37%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

In the previous week, Akebia Therapeutics had 3 more articles in the media than Boundless Bio. MarketBeat recorded 4 mentions for Akebia Therapeutics and 1 mentions for Boundless Bio. Akebia Therapeutics' average media sentiment score of 0.68 beat Boundless Bio's score of -0.33 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Boundless Bio	Neutral
Akebia Therapeutics	Positive

Boundless Bio has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market.

Akebia Therapeutics has higher revenue and earnings than Boundless Bio. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A
Akebia Therapeutics	$236.20M	1.15	-$5.34M	-$0.11	N/A

33.9% of Akebia Therapeutics shares are held by institutional investors. 23.1% of Boundless Bio shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Akebia Therapeutics beats Boundless Bio on 11 of the 15 factors compared between the two stocks.

How does Boundless Bio compare to ProQR Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Boundless Bio (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

32.7% of ProQR Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 23.1% of Boundless Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ProQR Therapeutics has a beta of 0.06, meaning that its stock price is 94% less volatile than the broader market. Comparatively, Boundless Bio has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market.

ProQR Therapeutics has higher revenue and earnings than Boundless Bio. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	12.21	-$47.73M	-$0.46	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A

ProQR Therapeutics currently has a consensus target price of $7.50, suggesting a potential upside of 259.71%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe ProQR Therapeutics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Boundless Bio has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -223.51%. Boundless Bio's return on equity of -70.89% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-223.51%	-73.83%	-35.14%
Boundless Bio	N/A	-70.89%	-47.37%

In the previous week, ProQR Therapeutics had 3 more articles in the media than Boundless Bio. MarketBeat recorded 4 mentions for ProQR Therapeutics and 1 mentions for Boundless Bio. ProQR Therapeutics' average media sentiment score of 0.52 beat Boundless Bio's score of -0.33 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
ProQR Therapeutics	Positive
Boundless Bio	Neutral

Summary

ProQR Therapeutics beats Boundless Bio on 11 of the 15 factors compared between the two stocks.

How does Boundless Bio compare to Avidity Biosciences?

Boundless Bio (NASDAQ:BOLD) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Avidity Biosciences has higher revenue and earnings than Boundless Bio. Avidity Biosciences is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A
Avidity Biosciences	$35.84M	6.89	-$36.78M	-$2.15	N/A

Avidity Biosciences' return on equity of 0.00% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-70.89%	-47.37%
Avidity Biosciences	N/A	N/A	N/A

In the previous week, Avidity Biosciences had 3 more articles in the media than Boundless Bio. MarketBeat recorded 4 mentions for Avidity Biosciences and 1 mentions for Boundless Bio. Avidity Biosciences' average media sentiment score of 0.28 beat Boundless Bio's score of -0.33 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Boundless Bio	Neutral
Avidity Biosciences	Neutral

Avidity Biosciences has a consensus price target of $63.85, indicating a potential upside of 342.45%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avidity Biosciences	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.29

Summary

Avidity Biosciences beats Boundless Bio on 11 of the 12 factors compared between the two stocks.

Get Boundless Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BOLD vs. The Competition

Export

Metric	Boundless Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$65.16M	$4.02B	$7.26B	$12.91B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	-1.00	12.64	273.83	25.42
Price / Sales	N/A	1,362.02	676.21	123.96
Price / Cash	N/A	105.29	76.98	52.08
Price / Book	0.99	16.28	12.89	6.17
Net Income	-$58.20M	-$22.72M	$3.48B	$349.24M
7 Day Performance	0.14%	-1.62%	-0.36%	-1.42%
1 Month Performance	11.44%	10.88%	6.49%	2.53%
1 Year Performance	149.26%	53.32%	25.06%	15.84%

Boundless Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BOLD Boundless Bio	1.1083 of 5 stars	$2.86 -0.9%	N/A	+151.3%	$65.16M	N/A	N/A	64
CAMP CAMP4 Therapeutics	3.8399 of 5 stars	$4.14 -1.4%	$9.56 +131.0%	+147.4%	$263.56M	$3.50M	N/A	644	Insider Trade High Trading Volume
MGNX MacroGenics	2.9121 of 5 stars	$4.08 +1.0%	$6.33 +55.2%	+148.3%	$257.35M	$149.50M	N/A	430
AKBA Akebia Therapeutics	2.3135 of 5 stars	$0.94 +3.7%	$3.75 +299.0%	-68.5%	$251.20M	$236.20M	N/A	430	Analyst Downgrade
PRQR ProQR Therapeutics	4.0503 of 5 stars	$2.32 -1.3%	$7.50 +223.3%	-6.1%	$247.60M	$17.99M	N/A	180	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BOLD) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Boundless Bio (BOLD) Competitors

BOLD vs. CAMP, MGNX, AKBA, PRQR, and RNA

How does Boundless Bio compare to CAMP4 Therapeutics?

Summary

How does Boundless Bio compare to MacroGenics?

Summary

How does Boundless Bio compare to Akebia Therapeutics?

Summary

How does Boundless Bio compare to ProQR Therapeutics?

Summary

How does Boundless Bio compare to Avidity Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD vs. The Competition

Boundless Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Boundless Bio (BOLD) Competitors

BOLD vs. CAMP, MGNX, AKBA, PRQR, and RNA

How does Boundless Bio compare to CAMP4 Therapeutics?

Which has stronger earnings and valuation, BOLD or CAMP?

Does the media favor BOLD or CAMP?

Which has more risk & volatility, BOLD or CAMP?

Is BOLD or CAMP more profitable?

Do analysts prefer BOLD or CAMP?

Summary

How does Boundless Bio compare to MacroGenics?

Do analysts rate MGNX or BOLD?

Do insiders and institutionals have more ownership in MGNX or BOLD?

Is MGNX or BOLD more profitable?

Which has more volatility & risk, MGNX or BOLD?

Which has better valuation & earnings, MGNX or BOLD?

Does the media favor MGNX or BOLD?

Summary

How does Boundless Bio compare to Akebia Therapeutics?

Do analysts recommend BOLD or AKBA?

Is BOLD or AKBA more profitable?

Does the media refer more to BOLD or AKBA?

Which has more risk & volatility, BOLD or AKBA?

Which has higher valuation and earnings, BOLD or AKBA?

Do insiders and institutionals hold more shares of BOLD or AKBA?

Summary

How does Boundless Bio compare to ProQR Therapeutics?

Do institutionals and insiders hold more shares of PRQR or BOLD?

Which has more risk & volatility, PRQR or BOLD?

Which has better earnings & valuation, PRQR or BOLD?

Do analysts rate PRQR or BOLD?

Is PRQR or BOLD more profitable?

Does the media prefer PRQR or BOLD?

Summary

How does Boundless Bio compare to Avidity Biosciences?

Which has better valuation & earnings, BOLD or RNA?

Is BOLD or RNA more profitable?

Does the media prefer BOLD or RNA?

Do analysts recommend BOLD or RNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD vs. The Competition

Boundless Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools